3-azido-3-deoxy-1,2-O-isopropylidene-6-O-(p-toluenesulfonyl)-α-D-glucofuranose | 22169-72-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-azido-3-deoxy-1,2-O-isopropylidene-6-O-(p-toluenesulfonyl)-α-D-glucofuranose
• 英文别名: 3-azido-3-deoxy-1,2-O-isopropylidene-6-O-p-toluenesulphonyl-α-D-glucofuranose；3-azido-3-deoxy-6-O-toluene-p-sulphonyl-1,2-O-isopropylidene-α-D-glucofuranose；toluene-4-sulfonic acid 2-(6-azido-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxol-5-yl)-2-hydroxy-ethyl ester；[(2R)-2-[(3aR,5S,6S,6aR)-6-azido-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-5-yl]-2-hydroxyethyl] 4-methylbenzenesulfonate
• CAS: 22169-72-8
• 化学式: C₁₆H₂₁N₃O₇S
• 分子量: 399.425
• InChiKey: SVFBPRSWDWHWBQ-XLWJZTARSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  114
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  3-azido-3-deoxy-1,2-O-isopropylidene-6-O-(p-toluenesulfonyl)-α-D-glucofuranose 在 palladium on activated charcoal Amberlite IR 120 (H+) 、 氢气 、 sodium acetate 作用下， 以 甲醇 、 乙醇 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 22.0h， 生成 methyl 3,6-acetylepimino-3,6-dideoxy-2,5-dithiocarbamoyl-(α,β)-D-glucofuranoside
  参考文献：
  名称：

  Gurjar, M. K.; Patil, V. J.; Pawar, S. M., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1987, vol. 26, # 1-12, p. 1115 - 1120

  摘要：

  DOI：
• 作为产物：
  描述：

  1,2:5,6-di-O-isopropylidene-3-O-trifluoromethanesulfonyl-α-D-allofuranose 在 吡啶 、 sodium azide 、 溶剂黄146 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 44.0h， 生成 3-azido-3-deoxy-1,2-O-isopropylidene-6-O-(p-toluenesulfonyl)-α-D-glucofuranose
  参考文献：
  名称：

  3,6-dideoxy-3,6-imino-1,2-o-isopropylidene-α-d-glucofuranose as a divergent intermediate for the synthesis of hydroxylated pyrrolidines; synthesis of 1,4 dideoxy-1,4-imino-l-gulitol, 1,4-dideoxy-i,4-imino-d-lyxitol, 2S,3S,4R-3,4-dihydroxyproline and (1S,2R,8S,8aR)-1,2,8-trihydroxyoctahydroindolizine [8-epi swainsonine]. X-ray crystal structure of (1S,2R,8S,8aR)-1,2,8-trihydroxy-5-oxo octahydroindolizine

  摘要：

  DOI：

  10.1016/s0040-4020(01)86851-4

文献信息

• [EN] CYSTEINE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE CYSTEINE PROTEASE
  申请人：MEDIVIR AB

  公开号：WO2005066180A1

  公开（公告）日：2005-07-21

  A compound of the formula (II) wherein one of R1 and R2 is halo and the other is H or halo; R3 is C1-C4 straight or branched chain, optionally fluorinated, alkyl; R4 is H; or R3 together with R4 and the adjoining backbone carbon defines: a spiro-C5-C7 cycloalkyl, optionally substituted with 1 to 3 substituents selected from halo, hydroxyl, C1-C4 alkyl or C1-C4 haloalkyl; or optionally bridged with a methylene group; or a C4-C6 saturated heterocycle having a hetero atom selected from O, NRa, S, S(=O)2 ; where Ra is H, C1-C4 alkyl or CH3C(=O); R5 is independently selected from H or methyl; E is -C(=O)-, -S(=O)m-, -NR5S(=O)m-, -NR5C(=O)-, -OC(=O)-, R6 is a stable, optionally substituted, monocyclic or bicyclic, carbocycle or hetorocycle; m is independently 0,1 or 2; are inhibitors of cathepsin K and useful in the treatment or prophylaxis of osteoporosis.

  一个公式为(II)的化合物，其中R1和R2中的一个是卤素，另一个是H或卤素；R3是C1-C4直链或支链，可选择氟代的烷基；R4是H；或者R3与R4和相邻的骨架碳一起定义：一个螺环C5-C7环烷基，可选地用1至3个卤素、羟基、C1-C4烷基或C1-C4卤代烷基中的取代基取代；或者可选地用亚甲基桥接；或者是一个具有O、NRa、S、S(=O)2等异原子的C4-C6饱和杂环；其中Ra是H、C1-C4烷基或CH3C(=O)；R5独立地选择自H或甲基；E是-C(=O)-、-S(=O)m-、-NR5S(=O)m-、-NR5C(=O)-、-OC(=O)-；R6是稳定的、可选择取代的、单环或双环的、碳环或杂环；m独立地为0、1或2；是猫hepsin K的抑制剂，并且在骨质疏松症的治疗或预防中有用。
• Synthesis, conformational study, glycosidase inhibitory activity and molecular docking studies of dihydroxylated 4- and 5-amino-iminosugars
  作者：Vijay M. Kasture、Navnath B. Kalamkar、Roopa J. Nair、Rakesh S. Joshi、Sushma G. Sabharwal、Dilip D. Dhavale

  DOI：10.1016/j.carres.2015.03.004

  日期：2015.5

  An efficient methodology for the synthesis of new amino iminosugars 6a, 7a and 8, starting from D-glucose, is reported. The conformational study using (1)H NMR data showed that the amino iminosugar 6a exists in the (2)C5 while; the 7a and 8 exist in the (5)C2 conformation. The inhibition activities with different glycosidases showed that 6a and 7a are poor glycosidase inhibitors. However, amino iminosugar

  报道了一种从D-葡萄糖开始合成新的氨基亚氨基糖6a，7a和8的有效方法。使用（1）H NMR数据进行的构象研究表明，氨基亚氨基糖6a存在于（2）C5中；7a和8以（5）C2构象存在。不同糖苷酶的抑制活性表明6a和7a是不良的糖苷酶抑制剂。然而，氨基亚氨基糖8显示出对β-半乳糖苷酶的选择性抑制（IC50 = 43μM，Ki = 153μM）。这些结果通过分子对接研究得到证实。
• Cysteine Protease Inhibitors
  申请人：Tickle David

  公开号：US20090023747A1

  公开（公告）日：2009-01-22

  A compound of the formula (II) wherein one of R 1 and R 2 is halo and the other is H or halo; R 3 is —C 1 -C 5 straight or branched chain, optionally fluorinated, alkyl or —CH 2 CR 5 C 3 -C 4 -Cycloalkyl; R 4 is H; R 5 is H, C 1 -C 2 alkyl, C 1 -C 2 haloalkyl, hydroxyl, OC 1 -C 2 alkyl, fluoro; R 6 is a stable, optionally substituted, monocyclic or bicyclic, carbocycle or heterocycle wherein the or each ring has 4, 5 or 6 ring atoms and 0 to 3 hetero atoms selected from S, O and N; Rb is haloalkyl; Rc is H or C 1 -C 4 alkyl; and pharmaceutically acceptable salts, hydrates or N-oxides thereof have utility in the treatment of disorders characterised by inappropriate expression or activation of cathepsin K, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.

  化合物的公式（II），其中R1和R2中的一个是卤素，另一个是氢或卤素; R3是直链或支链，可选择氟化的C1-C5烷基或-CH2CR5C3-C4环烷基; R4是氢; R5是氢，C1-C2烷基，C1-C2卤代烷基，羟基，OC1-C2烷基，氟; R6是稳定的，可选地取代的单环或双环，碳环或杂环，其中每个环具有4、5或6个环原子和0到3个从S、O和N中选择的杂原子; Rb是卤代烷基; Rc是氢或C1-C4烷基;以及其药学上可接受的盐，水合物或N-氧化物在治疗由于cathepsin K不适当的表达或激活而表现出来的疾病中具有用途，如骨质疏松症、骨关节炎、类风湿性关节炎或骨转移。
• Furo[3,2-B] pyrrol -3-one derivatives and their use as cysteinyl porteinase inhibitors
  申请人：Quibell Martin

  公开号：US20100010009A1

  公开（公告）日：2010-01-14

  The present invention relates to compounds of formula (1), and pharmaceutically acceptable salts thereof, A compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof (I), wherein: one of R 1 and R 2 is H, and the other is selected from F and Cl, or R 1 and R 2 are both F; R 3 is selected from cyclopentyl and cyclohexyl; R 4 is an optionally substituted 5- or 6-membered monocyclic or an 8- to 10-membered bicyclic aryl or heteroaryl ring which includes up to four heteroatoms. The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, diseases involving matrix or cartilage degradation, and bone cancer disorders such as bone metastases and associated pain.

  本发明涉及式（1）的化合物及其药学上可接受的盐，式（I）的化合物或药学上可接受的盐、水合物、配合物或前药，其中：R1和R2中的一个为H，另一个为F和Cl中的一种，或R1和R2均为F；R3选自环戊基和环己基；R4为可选取代的5-或6-成员单环或8-到10-成员的双环芳基或杂环芳基环，其中包含最多四个杂原子。本发明还涉及包括式（I）的化合物的制药组合物，并且在治疗骨质疏松症、帕盖特病、查加斯病、疟疾、牙龈疾病、高钙血症、代谢性骨病、涉及基质或软骨降解的疾病以及骨癌疾病如骨转移和相关疼痛中使用这种化合物的用途。
• Cysteine Protease inhibitors
  申请人：Nilsson Magnus

  公开号：US20080234260A1

  公开（公告）日：2008-09-25

  A compound of the formula II wherein one of R 1 and R 2 is halo and the other is H or halo; R 3 is C 1 -C 4 straight or branched chain, optionally fluorinated, alkyl; R 4 is H; or R 3 together with R 4 and the adjoining backbone carbon defines: a spiro-C 5 -C 7 cycloalkyl, optionally substituted with 1 to 3 substituents selected from halo, hydroxyl, C 1 -C 4 alkyl or C 1 -C 4 haloalkyl; or optionally bridged with a methylene group; or a C 4 -C 6 saturated heterocycle having a hetero atom selected from O, NRa, S, S(═O) 2 ; where Ra is H, C 1 -C 4 alkyl or CH 3 C(═O); R 5 is independently selected from H or methyl; E is —C(═O)—, —S(═O) m —, —NR 5 S(═O) m —, —NR 5 C(═O)—, —OC(═O)—, R 6 is a stable, optionally substituted, monocyclic or bicyclic, carbocycle or heterocycle; m is independently 0,1 or 2; are inhibitors of cathepsin K and useful in the treatment or prophylaxis of osteoporosis.

  化合物II的公式为其中R1和R2中的一个是卤素，另一个是氢或卤素;R3是C1-C4直链或支链，可选择氟代的烷基;R4是氢;或R3与R4和相邻的骨架碳一起定义:一个螺旋C5-C7环烷基，可选地被1至3个取代基所取代，所述取代基选自卤素、羟基、C1-C4烷基或C1-C4卤代烷基;或者可选地通过亚甲基基桥接;或者是一个C4-C6饱和杂环，其中杂原子选自O、NRa、S、S(═O)2;其中Ra是H、C1-C4烷基或CH3C(═O);R5是独立选择的H或甲基;E是—C(═O)—、—S(═O)m—、—NR5S(═O)m—、—NR5C(═O)—、—OC(═O)—;R6是稳定的、可选地取代的、单环或双环、碳环或杂环;m独立地为0、1或2;是猫hepsin K的抑制剂，用于治疗或预防骨质疏松症。